Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT05570825 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT05570825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05570825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
April 6, 2023
Completion date
July 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iiic lung cancer ajcc v8, stage iv lung cancer ajcc v8